AF
RNAM

Amalgamated Financial’s Avidity Biosciences RNAM Stock Holding History

Amalgamated Financial’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$89K Buy
+4,809
New +$81.7K ﹤0.01% 2193

Other funds holding RNAM

AWA
Aaron Wealth Advisors Chicago, Illinois $1.97B AUM 36.91% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Amalgamated Financial's RNAM Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Avidity Biosciences (RNAM) in Q1 2022: 4,809 shares worth $89K. The stake represents ﹤0.01% of the portfolio and ranks #2193 among its holdings.

103 funds tracked by Wall St. Rank hold RNAM as of Q1 2022.

  • Amalgamated Financial held 4,809 shares of Avidity Biosciences worth $89K as of Q1 2022.
  • Avidity Biosciences was a new Amalgamated Financial position in Q1 2022.
  • Avidity Biosciences made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2193 holding.
  • 103 funds tracked by Wall St. Rank held Avidity Biosciences as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.